Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This early-phase study tested a new drug called TQB2210 in 16 people with advanced cancers that had not responded to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block their growth. The main goals were to find a saf…

This study tested a new medicine called TQC2731, given as an injection, to see if it is safe and works well for people with long-term sinus inflammation and nasal polyps (growths in the nose). The trial involved 59 adults who had already completed a previous study of the same dru…

This study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The goal was to see if it could safely clear skin patches and improve symptoms over 12 weeks. Researchers measured how much skin improved using standard psoriasis scores.

This Phase 2 trial tested an injection called TQC2938, a humanized monoclonal antibody, in 136 adults with seasonal allergic rhinitis. All participants also used a standard nasal spray. The study measured how well the injection reduced nasal symptoms like sneezing and congestion …